The share price of this company has plummeted to an alltime low. Nevertheless the company seems to have a great beneficial FDA approved product called Phexxi which has huge potential and is currently being launched. The reason for the share price drop on Friday was probably that the CEO has sold some shares. Reading some forums it appears the reasons of her selling some of her shares are of private nature and are quite reasonable. I have not bought any shares yet, but will consider if I free up funds elsewhere... Information on the potential of Phexxi https://www.nasdaq.com/articles/3-top-biotech-stocks-with-fda-approvals-on-the-horizon-2020-04-19 EVFM earnings call for the period ending June 30, 2020. https://evofem.investorroom.com/download/2020.08.04_EVFM+Q2+2020+Transcript_FINAL.pdf Evofem Announces Pricing of Approximately $100 Million Public Offering of Common Stock https://evofem.investorroom.com/202...y-100-Million-Public-Offering-of-Common-Stock
This one is doing pretty well recently. I listened to one of their recent webcasts. If the roll-out of their product launch is succesful this will make nice returns.
Finally bought a first position in the past couple of days. I am very confident that EVFM has a high chance of a nice return on investment 12 months down the road ($8-$10). If Phexxi is a success the market cap is way too low. Current price is $2.35 Below are some interesting items from the recent Q3 Conference Call November 9: https://seekingalpha.com/article/43...r-on-q3-2020-results-earnings-call-transcript In the second half of 2020 Evofem has achieved three significant milestones. In September, we launched Phexxi, the first and only non-hormonal prescription contraceptive drugs for on-demand use. In October we closed the $25 million strategic investment from Adjuvant Capital. And we initiated our pivotal Phase III trial of EVO100 for the prevention of chlamydia and the prevention of gonorrhea in women (Adjuvant Capital invested because of this product). On September 8, we announced the commercial launch of Phexxi despite the challenges, we faced launching a commercial product in the midst of COVID-19, we are proud of our early momentum and we're confident about the long-term success of Phexxi, considering that there are 21 million women in the United States who are beyond hormones. Phexxi has conservatively a billion-dollar market opportunity, in fact, so listen to this part. If we can just acquire 3% of these 21 million women that's just 630,000 women out of the 21 million that are already beyond hormones and they fill their prescriptions seven times in one year, we will achieve this potential. Once again, this illustrates that small percentages of market share will deliver very big results for Phexxi. For well over a year, we built a strong relationship with Adjuvant Capital, they are backed by the Bill and Melinda Gates Foundation and other global public health leaders like Merck and Novartis. Adjuvant is deeply aligned with our core mission, developing and commercializing innovative products to address critical sexual and reproductive health concerns of women. There are $25 million investment without a premium to the market on the date of close, as well as the premium to the fundraising round we completed in June. This is Adjuvant’s largest single investment to-date. What is important is that what that testifies to is the confidence that they have in this team and the importance of introducing true innovation in women's health, not just me too products in crowded categories. Phexxi is off to a strong start. Right out of the gate healthcare providers started writing Phexxi prescriptions. In third quarter, which includes only the first three weeks of data, Phexxi was able to achieve 385 prescriptions, and we had our first refill before the quarter closed. I look forward to sharing more robust data on our Q4 earnings call in March when we'll have a full quarter plus of data to share and to give us a better idea of the launch trajectory. I want to conclude with a look at the market opportunity for Phexxi. Among the millions of women in the United States who are at risk for pregnancy, and importantly, unintended pregnancy, there are three distinct segments we will target for Phexxi. Our primary segments are first, women using no contraception at all. And also these women who are using non-prescription contraception such as barrier methods, withdraw or periodic abstinence. Our second segment, or as some might say, later adopters are women who are currently using prescription contraception, but who may already be considering moving to a hormone free on-demand method. Phexxi's peak revenue potential is 1.4 to 2.3 billion by achieving only single-digit acquisition percentages of women in each of these three segments. Based on our early indicators of a positive trend and our planned DTC campaign, which will be launched at the end of January, we are confident we can achieve Phexxi's full potential. We closed the quarter with 86.7 million in unrestricted cash and as Saundra mentioned in October, we raised 25 million from Adjuvant Capital. This provides us with runway into the second half of 2021 based on current expense forecasts in cash firm and I want to highlight Phexxi revenue provides upside to this forecast.
Evofem Biosciences Wins Business Intelligence Group's BIG Innovation Award 2021 Evofem honored amongst best companies globally for outstanding innovation with first-in-class non-hormonal prescription contraceptive vaginal gel, Phexxi® January 12, 2021 9:05 AM EST https://www.streetinsider.com/PRNew...roups+BIG+Innovation+Award+2021/17812193.html
According to the CEO the big ad campaign for Phexxi will start on valentines day (14 February 2021). "It is going to get everybodies attention" https://evofem.investorroom.com/events EVFM Presentation at H.C. Wainwright BIOCONNECT 2021 Virtual Conference Monday, January 11, 2021
I have a feeling this one will make a nice run rather sooner than later. Up today on 3.5 times higher trading volume. The Market cap of $240 Million is still very low imo considering the potential of Phexxi alone. Excerpt Q3 Conference Call November 9, 2020 Phexxi has conservatively a billion-dollar market opportunity, in fact, so listen to this part. If we can just acquire 3% of these 21 million women that's just 630,000 women out of the 21 million that are already beyond hormones and they fill their prescriptions seven times in one year, we will achieve this potential. Once again, this illustrates that small percentages of market share will deliver very big results for Phexxi. https://seekingalpha.com/article/4387366-evofem-biosciences-inc-evfm-ceo-saundra-pelletier-on-q3-2020-results-earnings-call-transcript
In my opinion EVFM has a good chance of doing very well in the weeks ahead. Market cap of $ 275 million is way too low. As I understand it, the DTC campaign starts on Valentines Day (February 14th). I think Phexxi will get a lot of attention especially on social media. Maybe Phexxi will get a like from Kim Kardashian... New presentation: Form 8-K filed by EVOFEM BIOSCIENCES, INC. on 2021-02-05 https://app.quotemedia.com/data/dow...02-05&CK=1618835#a2021feb_evfmxinvestorpr.htm
Somehow I have the feeling this one has a day of 100% gain potential relatively soon, at least I hope so. The big Direct To Consumer campaign for Phexxi starts on Valentine’s Day. Social media is hopefully going to make some noise because of the first and only hormone-free prescription contraception women control. Monday is a holiday so there will hopefully be some momentum come Tuesday…
EVOFEM JUST LAUNCHED THE WORLD'S 1ST NON-HORMONAL BIRTH CONTROL! Q1 SALES REPORT THIS MONTH! February 12, 2021
Once the impeachment stuff is over I hope the Democrats will focus on things which really matter for the American population. Where is Alexandria Ocasio-Cortez when you need her? Isn't this a hot topic for her? AOC absolutely has to make sure that every American woman can make the choice for the first and only hormone-free prescription contraception women control, regardless of their wallet. Come on AOC, make America great again This could all be upside potential for EVFM...
The word is spreading about Phexxi... What type of birth control do you use? Put it in the comments and let’s chat! 68.1K likes 20h ago https://www.tiktok.com/@gyno_girls/video/6929287808100125958
Now above $5. Still lots of upside potential imo considering the current market cap of $420 Million and the potential of Phexxi alone in the US. Europe and Asia are next...
February 22, 2021 https://www.sec.gov/Archives/edgar/data/0001618835/000161883521000022/a20210222_evfmxndrxfinal.htm
Tomorrow after the market closes EVFM will report quarterly numbers. If there are any indications that Phexxi will be a success, the share price should move much higher in my opinion. However, I am not sure whether the numbers and the report tomorrow will provide these indications already. Telehealth appointments increased sixfold in the week after the start of the Direct to Consumer Campaign on February 14th. The following is interesting for the overall picture: Over 960 women have booked appointments through the Phexxi Concierge Experience ™ to date~ 97% of these women left with a Phexxi prescription 82% of all women surveyed are somewhat to very likely to tell a friend or family member about Phexxi
I am licking my wounds today on this one. We are back a bit below my entry point. The conference call from yesterday was not bad imo. Phexxi has potential imo. I will add to my position once I free up funds elsewhere. Edited Transcript of Evofem Biosciences Inc earnings conference call or presentation Thursday, March 4, 2021 https://finance.yahoo.com/finance/news/edited-transcript-evfm-oq-earnings-213000231.html "We estimate every 1% increase in Phexxi awareness translates to approximately $30 million in gross revenue." “In just the first two weeks after Get Phexxi launched, our ad generated 115 million views and impressions across all media channels. Phexxi brand awareness doubled from January. To put this in perspective, we were tracking at about 4%. And it was literally like flipping a switch. We went boom immediately to 8% in one month.”
Form 4 - Statement of changes in beneficial ownership of securities March 9, 2021 https://app.quotemedia.com/data/dow...c.&formType=4&dateFiled=2021-03-09&CK=1618835 PELLETIER SAUNDRA L Purchase of 45,249 shares at $2.28
March 17, 2021 https://evofem.investorroom.com/202...ign-Get-Phexxi-Delivers-Strong-Initial-Impact Evofem Biosciences' DTC Campaign "Get Phexxi" Delivers Strong Initial Impact - Over 2,400 Phexxi units dispensed in February 2021, up 30% from prior month - - Accelerating retail demand drove 73% increase in ex-factory sales month-over-month - - Ex-factory sales YTD 2021 through mid-March have exceeded FY 2020 levels -
Recent news indicates that hormone based birth control pills are probably not a great thing. This is very good for Phexxi... Viral TikTok Highlights How Birth Control Pills Have Higher Blood Clot Risk Than AstraZeneca Vaccine 3/19/21 https://www.newsweek.com/viral-tikt...r-blood-clot-risk-astrazeneca-vaccine-1577527 Scientists probe new theories on whether AstraZeneca shot linked to blood clots March 20, 2021 “…others are trying to understand whether the cases are linked with birth control pills.” https://www.reuters.com/article/us-health-coronavirus-vaccine-idUSKBN2BC01M
